Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The vasomotor symptoms treatment market size was estimated to be worth USD 8.8 billion in 2022. Driven by the rise in the number of vasomotor symptoms cases, the market is expected to rise at a CAGR of 6.70% during the forecast period of 2023-2031 to attain a value of more than USD 15.7 billion by 2031.
Vasomotor symptoms are the symptoms that occur during menopause due to the constriction of blood vessels. The common vasomotor symptoms include hot flashes, night sweats, and changes in blood pressure.
Vasomotor symptoms occur at menopause because of the substantial hormonal changes that can affect the blood pressure and temperature regulator of the body. The significant estrogen level decrease triggers the nervous system, making the patient restless.
Vasomotor symptoms are more prevalent in African Americans than in Asian Americans. Smoking and obesity further increase the chances of this disorder.
The management of vasomotor symptoms is done using medications. The first-line treatment includes the use of hormonal regulators and anti-depressant drugs. Several lifestyle remedies are also incorporated to manage vasomotor symptoms.
According to the vasomotor symptoms treatment market research report, the market can be categorised into the following segments:
Market Breakup by Route of Administration
Market Breakup by Type of Therapy
Market Breakup by Distribution Channel
Market Breakup by Region
The rising prevalence of vasomotor symptoms, such as hot flashes and night sweats during menopausal phases, is anticipated to boost the market growth. According to the International Journal of Applied & Basic Medical Research, nearly 88% of women reported menopausal and vasomotor symptoms, thus facilitating the demand for more therapeutic options.
The increasing investments in the research and development activities by the key players are driving the treatment of the vasomotor symptoms treatment market development. This further contributes to the discovery of novel therapeutic interventions, that will propel the market expansion.
Additional factors, such as a rise in the adoption of a sedentary lifestyle, an increase in the number of mergers and acquisitions, and raising awareness regarding vasomotor symptoms are attributing to the growth of the market.
North America is anticipated to account for the largest revenue share of the global market. This is due to the high incidence of post-menopausal symptoms, raising awareness about women’s health, and increasing expenditure in the healthcare sector. The significant presence of key global players in this region is also projected to boost the market growth.
During the forecast period, Latin America is expected to witness the fastest growth in the vasomotor symptoms treatment market. The factors leading to this rapid growth include the rising awareness regarding menopausal symptoms and more significant expenditure in the research and development sector.
There are several therapeutic interventions for the management of vasomotor symptoms. The procedures used for the treatment of vasomotor symptoms are pharmacological and non-pharmacological. In pharmacological ones, there are two main primary therapies, hormonal replacement therapy (HRT) and non-hormonal medications.
During menopause, there is a substantial reduction in the levels of oestrogen and progesterone. Hormonal replacement therapies are generally utilised to restore reduced hormonal levels, which will subsequently help regulate average body temperature. There are two hormone replacement therapies, oestrogen therapy and oestrogen progesterone hormone therapy.
Hormonal replacement therapies have associated adverse effects; therefore, there is a shift toward non-hormonal medications. Different medications can be incorporated into the treatment regimen depending on the vasomotor symptoms. Serotonin reuptake inhibitors, such as citalopram and fluoxetine, are generally used for hot flashes.
Other medications, such as antidepressants, anti-seizure, urinary, blood pressure, and over-the-counter drugs, also help alleviate vasomotor symptoms.
Alternative treatments, including acupuncture, hypnosis, meditation, and relaxation techniques, have been beneficial for managing menopausal and vasomotor symptoms.
The currently available therapies are associated with several adverse effects and thus leading to several other diseases and comorbidities. Hence, scientists are performing clinical trials for novel therapeutic interventions that will be more effective and have fewer side effects.
M2S Hot Flash Study, an ongoing clinical trial by Fervent Pharmaceuticals, is being performed to manage vasomotor symptoms. This virtual Phase II clinical trial treats moderate night sweats and hot flashes. The primary objective is to analyse the safety and efficacy of peri and post-menopausal therapy.
Astellas Pharma, a key player, is performing a SKYLIGHT 4 clinical trial study to assess the safety and efficacy of fezolinetant, a non-hormonal therapy. Phase III trials are under process for testing the safety and tolerability of this investigational selective neurokinin three receptor antagonist on endometrial health.
Another set of clinical trials is undergoing for the novel neurokinin three receptor antagonist, which is anticipated to provide the potential treatment for managing vasomotor symptoms. Acer Therapeutics is conducting Phase II clinical trials for its ACER-801 (osanetant) drug, and if successfully approved can benefit in the alleviation of vasomotor symptoms.
With the increasing number of key players, there is a rise in the number of drugs under the pipeline. These novel products' approval and launch are expected to boost the market growth.
The report gives an in-depth analysis of the key players involved in the vasomotor symptoms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Route of Administration||
|Breakup by Type of Therapy||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Vasomotor Symptoms Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Vasomotor Symptoms Treatment Market
6.1 Global Vasomotor Symptoms Treatment Market Overview
6.2 Global Vasomotor Symptoms Treatment Market Analysis
6.2.1 Market Overview
184.108.40.206 Global Vasomotor Symptoms Treatment Market Historical Value (2016-2022)
220.127.116.11 Global Vasomotor Symptoms Treatment Market Forecast Value (2023-2031)
6.3 Global Vasomotor Symptoms Treatment Market by Route of Administration
6.3.1 Market Overview
6.4 Global Vasomotor Symptoms Treatment Market by Type of Therapy
6.4.1 Market Overview
18.104.22.168 Hormonal Therapies
22.214.171.124.1 Estrogen Replacement Therapies
126.96.36.199.2 Pregestational Therapies
188.8.131.52 Non-Hormonal Therapies
184.108.40.206.2 Serotonin Reuptake Inhibitors
6.5 Global Vasomotor Symptoms Treatment Market by Distribution Channel
6.5.1 Market Overview
220.127.116.11 Hospital Based Pharmacies
18.104.22.168 Online Pharmacies
22.214.171.124 Retail Pharmacies
6.6 Global Vasomotor Symptoms Treatment Market by Region
6.6.1 Market Overview
126.96.36.199 North America
188.8.131.52.1 Historical Trend (2016-2022)
184.108.40.206.2 Forecast Trend (2023-2031)
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
22.214.171.124 Asia Pacific
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
184.108.40.206 Latin America
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
22.214.171.124 Middle East and Africa
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
7 North America Vasomotor Symptoms Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Vasomotor Symptoms Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Vasomotor Symptoms Treatment Market
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Vasomotor Symptoms Treatment Market
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Vasomotor Symptoms Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials
12.2 Patent Landscape
12.2.1 Patent Overview
184.108.40.206 Patent Status and Expiry
220.127.116.11 Timelines from Drug Development to Commercial Launch
18.104.22.168 New Drug Application
22.214.171.124.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
126.96.36.199 US FDA
188.8.131.52 EU EMA
184.108.40.206 INDIA CDSCO
220.127.116.11 JAPAN PMDA
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Vasomotor Symptoms Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Bayer AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Fervent Pharmaceuticals, LLC
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Astellas Pharma Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Frazier Healthcare Partners
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Mitsubishi Tanabe Pharma Corporation
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Eli Lilly and Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 AbbVie Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 AMAG Pharmaceuticals Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Emcure Pharmaceuticals Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Merck & Co., Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Novartis AG
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 Novo Nordisk A/S
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.13 Pfizer Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.14 Teva Pharmaceutical Industries Ltd.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
16 Recommendations and Discussion
17 Global Vasomotor Symptoms Treatment Drugs Distribution Model (Additional Insight)
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of USD 8.8 billion in 2022, driven by the rising prevalence of the disease.
The market is likely to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to attain a value of USD 15.7 billion by 2031.
The increasing prevalence of vasomotor symptoms, evolving healthcare infrastructure, and more significant investments in the research and development sector are primarily driving the market growth.
Based on the route of administration, the market can be segmented into oral, parenteral, and topical.
Based on the therapy type, the market is divided into hormonal and non-hormonal therapies, among others.
Based on the distribution channel, the market can be categorised into hospital pharmacies, online pharmacies, and retail pharmacies.
On a regional level, the market has been categorised into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America is anticipated to hold the maximum share in the market.
The key companies involved in the market are Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., and Teva Pharmaceutical Industries Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.